Topics

Sandoz Optimistic On Biosimilars As It Reprioritizes US Portfolio

12:15 EST 14 Feb 2020 | SCRIP

Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis...

      

Related Stories

 

Original Article: Sandoz Optimistic On Biosimilars As It Reprioritizes US Portfolio

NEXT ARTICLE

More From BioPortfolio on "Sandoz Optimistic On Biosimilars As It Reprioritizes US Portfolio"

Quick Search

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...